What serious condition is associated with Aptivus (tipranavir)?

Aptivus (tipranavir) is primarily associated with an increased risk of intracranial bleeding. This serious condition can occur due to the drug’s effects on blood coagulation and the potential for venous thromboembolism, which can lead to hemorrhagic complications. The risk of intracranial bleeding is particularly highlighted in clinical data, indicating that patients taking Aptivus may have a predisposition to this severe side effect.

In considering the other options, while kidney failure, pancreatitis, and cardiac arrest are serious conditions, they are not specifically linked to the use of Aptivus in the same way. Knowing this context helps healthcare providers monitor patients more closely for the signs and symptoms of intracranial bleeding, ensuring timely intervention when necessary.